Angiotensin II receptors subtypes mediate diverse gene expression profile in adult hypertrophic cardiomyocytes

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 11, 2007, Pages 1191-1198

  Zhou, Juan ^a   Xu, Xin ^a   Liu, Jin Jun ^a   Lin, Yuan Xi ^a   Gao, Guang Dao ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Angiotensin II; Angiotensin II receptors; Cardiomyocytes; Gene array; Hypertrophy; Interleukin 1 ; Tumour necrosis factor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; RHO KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; MALE; NONHUMAN; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, ABDOMINAL; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMIDAZOLES; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIGATION; LOSARTAN; MALE; MYOCYTES, CARDIAC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PYRIDINES; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548677049     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04694.x     Document Type: Article

References (32)

1. Ardaillou R. Angiotensin II receptors. J. Am. Soc. Nephrol. 1999 10 (Sup pl S30 9.
2. 2 receptors: Regulation, signaling and function. Blood Press. 2003 : 12 : 70 88.
3. 2 receptors. J. Hypertens. 2001 19 : 1681 9.
4. Wollert KC, Drexler H. The renin-angiotensin system and experimental heart failure. Cardiovasc. Res. 1999 43 : 838 49.
5. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in the myocardial growth and hypertrophy. Circ. Res. 1993 73 : 439 47.
6. 2-receptor subtypes in hypertrophied rat hearts. Am. J. Physiol. 1994 267 : H844 52.
7. Schunkert H, Weinberg EO, Bruckschlegel G, Riegger AJ, Lorell BH. Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding. J. Clin. Invest. 1995 96 : 2768 74.
8. Fares N, Bois P, Lenfant J, Potreau D. Characterization of a hyperpolarization-activated current in dedifferentiated adult rat ventricular cells in primary culture. J. Physiol. 1998 506 : 73 82.
9. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV. Potential role of MCP-1 in endothelial cell tight junction 'opening': Signaling via Rho and Rho kinase. J. Cell Sci. 2003 116 : 4615 28.
10. Gesty-Palmer D, El Shewy H, Kohout TA, Luttrell LM. β-Arrestin 2 expression determines the transcriptional response to lysophosphatidic acid stimulation in murine embryo fibroblasts. J. Biol. Chem. 2005 280 : 32 157 67.
11. Noordewier MQ, Warren PV. Gene expression microarrays and the integration of biological knowledge. Trends Biotechnol. 2001 19 : 412 15.
12. 2receptors in cardiac hypertrophy and cardiac remodelling. Clin. Exp. Pharmacol. Physiol. 2003 30 : 911 18.
13. Schunkert H, Dzau VJ, Tang SS, Hirsh AT, Apstein C, Lorell B. Increased rat cardiac angiotensin converting enzyme activity and mRNA levels in pressure overload left ventricular hypertrophy: Effects on coronary resistance, contractility and relaxation. J. Clin. Invest. 1990 86 : 1913 20.
14. Zhang X, Dostal DE, Reiss K et al. Identification and activation of autocrine renin-angiotensin system in adult ventricular myocytes. Am. J. Physiol. 1995 269 : H1791 802.
15. Serneri GG, Boddi M, Cecioni I et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ. Res. 2001 88 : 961 8.
16. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 2000 52 : 11 34.
17. Hiroi Y, Hiroi J, Kudoh S, Yazaki Y, Nagai R, Komuro I. Two distinct mechanisms of angiotensin II-induced negative regulation of the mitogen-activated protein kinases in cultured cardiac myocytes. Hypertens. Res. 2001 24 : 385 94.
18. Batenburg WW, Tom B, Schuijt MP, Danser AH. Angiotensin II type 2 receptor-mediated vasodilation. Focus on bradykinin, NO and endothelium-derived hyperpolarizing factor(s). Vasc. Pharmacol. 2005 42 : 109 18.
19. Ruiz-Ortega M, Ruperez M, Esteban V et al. Angiotensin II: A key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant. 2006 21 : 16 20.
20. Barnes PJ, Karin M. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 1997 336 : 1066 71.
21. Sekiguchi K, Li X, Coker M et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc. Res. 2004 63 : 433 42.
22. Tsutamoto T, Wada A, Maeda K et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J. Am. Coll. Cardiol. 2000 35 : 714 21.
23. 2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J. Am. Soc. Nephrol. 2004 15 : 1514 29.
24. 2 in vascular smooth muscle cells: Molecular mechanisms. Circ. Res. 2000 86 : 1266 72.
25. 2 receptor blockade on ischaemia-reperfusion recovery in rat hearts. Pharmacol. Res. 2005 51 : 497 502.
26. 2 receptors. J. Hypertens. 2001 19 : 1681 9.
27. Okamoto K, Kato S, Arima N, Fuj IIT, Morimatsu M, Imaizumi T. Cyclin-dependent kinase inhibitor, p21Waf1, regulates vascular smooth muscle cell hypertrophy. Hypertens. Res. 2004 27 : 283 91.
28. Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE, Shankland SJ. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int. 1999 56 : 1691 9.
29. Mora A, Sakamoto K, McManus EJ, Alessi DR. Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett. 2005 579 : 3632 8.
30. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ. Res. 2002 8 : 135 42.
31. 2-adrenergic receptor overexpression. Endocrinology 2003 144 : 4097 105.
32. Robert P, Tsui P, Laville MP et al. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J. Mol. Cell. Cardiol. 2001 33 : 1589 606.